Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. Issue 5 (22nd December 2020)

• Record Type: Journal Article
• Authors: Van den Bosch, Ines; Bouillon, Thomas; Verhamme, Peter; Vanassche, Thomas; Jacquemin, Marc; Coemans, Maarten; Kuypers, Dirk; Meijers, Björn
• Is Part Of: Nephrology dialysis transplantation. Volume 36:Issue 5(2021)
• Page Start: 884
• Page End: 889
• Publication Date: 2020-12-22
• Subjects: apixaban -- DOAC -- dose-finding -- haemodialysis -- pharmacokinetics; Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa351
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background: Apixaban, a direct oral anticoagulant inhibiting factor Xa, has been proven to reduce the risk of atrial fibrillation-related stroke and thromboembolism in patients with mild to moderate renal insufficiency. Patients on renal replacement therapy, however, were excluded from randomized controlled trials. Therefore, uncertainty remains concerning benefits, dosing and timing of intake in haemodialysis population. Methods: We conducted a Phase II pharmacokinetics study in which 24 patients on maintenance haemodialysis were given a single dose (2.5 mg or 5 mg) of apixaban, either 30 min before or immediately after dialysis on the mid-week dialysis day. Results: Apixaban 5 mg resulted in higher area under the curve (AUC0–48 ) in comparison with 2.5 mg, although significance could only be reached for dosing pre-dialysis (2.5 mg versus 5 mg, P = 0.008). In line, peak concentrations (Cmax ) after dosing pre-dialysis were significantly higher in the 5 mg than in the 2.5 mg groups (P = 0.02). In addition, dialysis resulted in significant reduction of drug exposure. AUC0–48 pre-dialysis were on average 48% (2.5 mg) and 26% (5 mg) lower than the AUC0–48 post-dialysis, in line with Cmax . As a result, a dose of 2.5 mg post-dialysis and a dose of 5 mg pre-dialysis resulted in similar AUC0–48 . In contrast, significant differences were found between the 5 mg group post-dialysis and the 2.5 mg group pre-dialysis (P = 0.02). Conclusions: Our data suggest that exposure to apixaban in patients on maintenance haemodialysis is dependent not only on drug dose but also on timing of intake relative to the haemodialysis procedure. Graphical Abstract: